Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cidara Therapeutics, Inc.CDTX · Entity 69639 | Chief Accounting Officer | September 18, 2017 | September 19, 2017 |
| Crinetics Pharmaceuticals, Inc.CRNX · Entity 3579 | CFO | December 31, 2024 | January 29, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cidara Therapeutics, Inc.
Report date September 18, 2017 · Filed September 19, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,356 |
Reported balance
After 2017-09-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-09-18 · Grant · Acquired 5,000 · Balance 10,356 F1: 1/3rd of the total number of shares subject to the restricted stock unit shall vest on each December 31 of 2018, 2019 and 2020. F2: Includes 1,414, 1,603, 350, and 1,989 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on November 20, 2015, May 20, 2016, November 18, 2016 and May 19, 2017, respectively. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 10,000 |
Reported balance
After 2017-09-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-09-18 · Exercise / conversion · Acquired 10,000 · Balance 10,000 F3: Restricted stock units convert into common stock on a one-for-one basis. F4: A portion of the shares vest upon the achievement of various clinical and corporate milestones. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/3rd of the total number of shares subject to the restricted stock unit shall vest on each December 31 of 2018, 2019 and 2020.
F2: Includes 1,414, 1,603, 350, and 1,989 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on November 20, 2015, May 20, 2016, November 18, 2016 and May 19, 2017, respectively.
F3: Restricted stock units convert into common stock on a one-for-one basis.
F4: A portion of the shares vest upon the achievement of various clinical and corporate milestones.
Crinetics Pharmaceuticals, Inc.
Report date December 31, 2024 · Filed January 29, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 111,565 |
Reported balance
After 2024-11-20 transaction · row 1
1 source rowRow 1 · 2024-11-20 · Other · Acquired 473 · Balance 111,565 F1: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c), |
Filing footnotes · ownership attribution and instrument terms
F1: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c),
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 20, 2024 Filed Jan 29, 2025 21:30 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | OtherCommon Stock | 473 | $14.98 | $7,085.54 |
DisclosureSEC source: 0000950170-25-010530 · ownership.xml · nonDerivative · entry 1 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,565 F1 · date: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c), Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 21:01 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionStock option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $15.29 | $0.00 |
DisclosureSEC source: 0000950170-24-110416 · ownership.xml · derivative · entry 3 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,000 Underlying: Common Stock · 25,000 shares Expires 2031-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/48th of the shares subject to the option vested on March 26, 2021, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 21:01 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 25,000 | $51.11 | $1,277,750.00 |
DisclosureSEC source: 0000950170-24-110416 · ownership.xml · nonDerivative · entry 2 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,092 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $51.11 per share. The range of sales prices on the transaction date was $50.28 to $51.54 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 21:01 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionCommon Stock | 25,000 | $15.29 | $382,250.00 |
DisclosureSEC source: 0000950170-24-110416 · ownership.xml · nonDerivative · entry 1 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,092 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 25, 2024 Filed Jul 26, 2024 20:24 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionStock option (Right to Buy) · Derivative | 19,056 | $0.00 Strike: $9.28 | $0.00 |
DisclosureSEC source: 0000950170-24-086913 · ownership.xml · derivative · entry 3 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,056 shares Expires 2028-05-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| July 25, 2024 Filed Jul 26, 2024 20:24 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 19,056 | $53.88 | $1,026,737.28 |
DisclosureSEC source: 0000950170-24-086913 · ownership.xml · nonDerivative · entry 2 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,092 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $53.88 per share. The range of sales prices on the transaction date was $53.12 to $54.23 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document |
| July 25, 2024 Filed Jul 26, 2024 20:24 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionCommon Stock | 19,056 | $9.28 | $176,839.68 |
DisclosureSEC source: 0000950170-24-086913 · ownership.xml · nonDerivative · entry 1 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 21:14 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionStock option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $20.02 | $0.00 |
DisclosureSEC source: 0000950170-24-084328 · ownership.xml · derivative · entry 3 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,000 Underlying: Common Stock · 25,000 shares Expires 2032-02-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/48th of the shares subject to the option vested on March 31, 2022, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 21:14 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 25,000 | $55.00 | $1,375,000.00 |
DisclosureSEC source: 0000950170-24-084328 · ownership.xml · nonDerivative · entry 2 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,092 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 21:14 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionCommon Stock | 25,000 | $20.02 | $500,500.00 |
DisclosureSEC source: 0000950170-24-084328 · ownership.xml · nonDerivative · entry 1 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,092 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 20:32 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionStock option (Right to Buy) · Derivative | 32,129 | $0.00 Strike: $9.28 | $0.00 |
DisclosureSEC source: 0000950170-24-080557 · ownership.xml · derivative · entry 3 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,056 Underlying: Common Stock · 32,129 shares Expires 2028-05-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 20:32 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 32,129 | $43.61 | $1,401,145.69 |
DisclosureSEC source: 0000950170-24-080557 · ownership.xml · nonDerivative · entry 2 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,092 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $43.61 per share. The range of sales prices on the transaction date was $43.28 to $44.13 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. F3 · balance_after: Includes 462 shares acquired under the Issuer's Employee Stock Purchase Plan. Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 20:32 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionCommon Stock | 32,129 | $9.28 | $298,157.12 |
DisclosureSEC source: 0000950170-24-080557 · ownership.xml · nonDerivative · entry 1 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,221 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 19, 2024 Filed Mar 20, 2024 22:32 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 6,942 | $42.91 | $297,881.22 |
DisclosureSEC source: 0001209191-24-005009 · doc4.xml · nonDerivative · entry 2 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,630 F2 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan. F3 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $42.91 per share. The range of sales prices on the transaction date was $41.04 to $44.00 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 22:32 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Tax withholdingCommon Stock | 3,983 | $38.14 | $151,911.62 |
DisclosureSEC source: 0001209191-24-005009 · doc4.xml · nonDerivative · entry 1 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,572 F1 · kind: Represents the number of shares of common stock withheld by the Issuer to cover the reporting person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022 and March 1, 2023. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 01:01 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 95,500 | $0.00 Strike: $43.51 | $0.00 |
DisclosureSEC source: 0001209191-24-004609 · doc4.xml · derivative · entry 2 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,500 Underlying: Common Stock · 95,500 shares Expires 2034-03-03 F2 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of March 4, 2024. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 01:01 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantCommon Stock | 25,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-004609 · doc4.xml · nonDerivative · entry 1 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,555 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2025. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:43 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionNon-qualified stock option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $9.28 | $0.00 |
DisclosureSEC source: 0001209191-24-000812 · doc4.xml · derivative · entry 3 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,185 Underlying: Common Stock · 10,000 shares Expires 2028-05-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:43 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 10,000 | $35.47 | $354,700.00 |
DisclosureSEC source: 0001209191-24-000812 · doc4.xml · nonDerivative · entry 2 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,055 F2 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan. F3 · price: The common stock was sold by the Reporting Person in open market transactions on the transaction date with a volume weighted average sales price of $35.47 per share. The range of sales prices on the transaction date was $34.41 to $36.07 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:43 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionCommon Stock | 10,000 | $9.28 | $92,800.00 |
DisclosureSEC source: 0001209191-24-000812 · doc4.xml · nonDerivative · entry 1 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 454 shares acquired under the Issuer's Employee Stock Purchase. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 23:38 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionNon-qualified stock option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $9.28 | $0.00 |
DisclosureSEC source: 0001209191-23-054425 · doc4.xml · derivative · entry 3 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,185 Underlying: Common Stock · 10,000 shares Expires 2028-05-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 23:38 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 10,000 | $28.75 | $287,500.00 |
DisclosureSEC source: 0001209191-23-054425 · doc4.xml · nonDerivative · entry 2 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,601 F2 · price: The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $28.75 per share. The range of sales prices on the transaction date was $28.14 to $29.07 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 23:38 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionCommon Stock | 10,000 | $9.28 | $92,800.00 |
DisclosureSEC source: 0001209191-23-054425 · doc4.xml · nonDerivative · entry 1 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,601 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 443 shares acquired under the Issuer's Employee Stock Purchase Plan. Read SEC document |
| June 20, 2023 Filed Jun 21, 2023 21:32 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionNon-qualified stock option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $9.28 | $0.00 |
DisclosureSEC source: 0001209191-23-038852 · doc4.xml · derivative · entry 4 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,185 Underlying: Common Stock · 20,000 shares Expires 2028-05-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| June 20, 2023 Filed Jun 21, 2023 21:32 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 20,000 | $19.97 | $399,400.00 |
DisclosureSEC source: 0001209191-23-038852 · doc4.xml · nonDerivative · entry 3 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,158 F2 · price: The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $19.97 per share. The range of sales prices on the transaction date was $19.86 to $20.32 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document |
| June 20, 2023 Filed Jun 21, 2023 21:32 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionCommon Stock | 20,000 | $9.28 | $185,600.00 |
DisclosureSEC source: 0001209191-23-038852 · doc4.xml · nonDerivative · entry 2 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2023 Filed Jun 21, 2023 21:32 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 10,922 | $19.96 | $218,003.12 |
DisclosureSEC source: 0001209191-23-038852 · doc4.xml · nonDerivative · entry 1 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,158 F1 · price: The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $19.96 per share. The range of sales prices on the transaction date was $19.86 to $20.32 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document |
| March 16, 2023 Filed Mar 17, 2023 21:11 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Tax withholdingCommon Stock | 1,666 | $17.12 | $28,521.92 |
DisclosureSEC source: 0001209191-23-019774 · doc4.xml · nonDerivative · entry 1 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,080 F1 · kind: Represents the number of shares of common stock withheld by the Issuer to cover the reporting person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:33 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 112,850 | $0.00 Strike: $19.64 | $0.00 |
DisclosureSEC source: 0001209191-23-015545 · doc4.xml · derivative · entry 2 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,850 Underlying: Common Stock · 112,850 shares Expires 2033-02-28 F2 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of March 1, 2023. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:33 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantCommon Stock | 24,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-015545 · doc4.xml · nonDerivative · entry 1 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,746 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2024. Read SEC document |
| November 20, 2022 Filed Jan 27, 2023 21:29 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | OtherCommon Stock | 482 | $11.02 | $5,311.64 |
DisclosureSEC source: 0001209191-23-005258 · doc5.xml · nonDerivative · entry 2 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,546 F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c), Read SEC document |
| May 20, 2022 Filed Jan 27, 2023 21:29 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | OtherCommon Stock | 1,446 | $11.02 | $15,934.92 |
DisclosureSEC source: 0001209191-23-005258 · doc5.xml · nonDerivative · entry 1 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,064 F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c), Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:00 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 91,000 | $0.00 Strike: $20.02 | $0.00 |
DisclosureSEC source: 0001209191-22-015132 · doc4.xml · derivative · entry 2 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,000 Underlying: Common Stock · 91,000 shares Expires 2032-02-27 F2 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 28, 2022. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:00 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantCommon Stock | 19,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015132 · doc4.xml · nonDerivative · entry 1 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,618 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2023.. Read SEC document |
| November 19, 2021 Filed Feb 4, 2022 21:30 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | OtherCommon Stock | 837 | $11.02 | $9,223.74 |
DisclosureSEC source: 0001209191-22-007202 · doc5.xml · nonDerivative · entry 2 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,118 F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c). Read SEC document |
| May 20, 2021 Filed Feb 4, 2022 21:30 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | OtherCommon Stock | 1,090 | $11.02 | $12,011.80 |
DisclosureSEC source: 0001209191-22-007202 · doc5.xml · nonDerivative · entry 1 Wilson Marc · CIK 0001702265 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,281 F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c). Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 22:23 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 114,000 | $0.00 Strike: $15.29 | $0.00 |
DisclosureSEC source: 0001209191-21-016263 · doc4.xml · derivative · entry 1 Wilson Marc · CIK 0001702265 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,000 Underlying: Common Stock · 114,000 shares Expires 2031-02-25 F1 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 26, 2021. Read SEC document |
| November 20, 2020 Filed Feb 5, 2021 21:43 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | OtherCommon Stock | 702 | $11.61 | $8,150.22 |
DisclosureSEC source: 0001209191-21-008100 · doc5.xml · nonDerivative · entry 2 Wilson Marc · CIK 0001702265 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,191 F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c), Read SEC document |
| May 20, 2020 Filed Feb 5, 2021 21:43 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | OtherCommon Stock | 697 | $14.45 | $10,071.65 |
DisclosureSEC source: 0001209191-21-008100 · doc5.xml · nonDerivative · entry 1 Wilson Marc · CIK 0001702265 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,489 F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c), Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:15 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $22.61 | $0.00 |
DisclosureSEC source: 0001209191-20-012987 · doc4.xml · derivative · entry 1 Wilson Marc · CIK 0001702265 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2030-02-23 F1 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 24, 2020. Read SEC document |
| May 20, 2019 Filed Feb 11, 2020 21:04 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | OtherCommon Stock | 1,471 | $14.45 | $21,255.95 |
DisclosureSEC source: 0001209191-20-008269 · doc5.xml · nonDerivative · entry 1 Wilson Marc · CIK 0001702265 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,792 F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c). F2 · balance_after: Includes 29,090 shares of restricted stock which remain subject to continued vesting. Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 22:43 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 56,250 | $0.00 Strike: $25.19 | $0.00 |
DisclosureSEC source: 0001209191-19-018983 · doc4.xml · derivative · entry 1 Wilson Marc · CIK 0001702265 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,250 Underlying: Common Stock · 56,250 shares Expires 2029-03-07 F1 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the Vesting Commencement Date of March 8, 2019. Read SEC document |
| November 20, 2018 Filed Feb 12, 2019 22:29 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | OtherCommon Stock | 1,470 | $14.45 | $21,241.50 |
DisclosureSEC source: 0000899243-19-003326 · doc5.xml · nonDerivative · entry 1 Wilson Marc · CIK 0001702265 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,321 F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c). F2 · balance_after: Includes 55,851 shares of restricted stock issued upon the Reporting Person's early exercise of a stock option that remain unvested. 25% of the restricted shares vested on January 4, 2019, and 1/48th of the total remaining number of restricted shares will vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| September 18, 2017 Filed Sep 19, 2017 16:44 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | Exercise / conversionRestricted Stock Unit · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-053301 · doc4.xml · derivative · entry 2 Wilson Marc · CIK 0001702265 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: A portion of the shares vest upon the achievement of various clinical and corporate milestones. F4 · derivative.expiration_date: A portion of the shares vest upon the achievement of various clinical and corporate milestones. Read SEC document |
| September 18, 2017 Filed Sep 19, 2017 16:44 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-053301 · doc4.xml · nonDerivative · entry 1 Wilson Marc · CIK 0001702265 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,356 F1 · shares: 1/3rd of the total number of shares subject to the restricted stock unit shall vest on each December 31 of 2018, 2019 and 2020. F2 · balance_after: Includes 1,414, 1,603, 350, and 1,989 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on November 20, 2015, May 20, 2016, November 18, 2016 and May 19, 2017, respectively. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 16:40 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | GrantEmployee Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-17-024853 · doc4.xml · derivative · entry 2 Wilson Marc · CIK 0001702265 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-03-30 F2 · derivative.exercise_date: The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 31, 2017. Read SEC document |
| March 16, 2016 Filed Apr 4, 2017 16:40 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | GrantEmployee Stock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $9.89 | $0.00 |
DisclosureSEC source: 0001209191-17-024853 · doc4.xml · derivative · entry 1 Wilson Marc · CIK 0001702265 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2026-03-15 F1 · derivative.exercise_date: The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 16, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.